PhorMed Inc. has recently filed a Form C to launch a Regulatory CF equity crowdfunding campaign on the WeFunder platform. The company aims to raise $5 million to support its clinical trials. PhorMed is a clinical stage biopharmaceutical company that uses cell-repair technology to treat diseases in oncology, inflammation, and neuroscience. Currently, the company has three indications in phase II, including Acute Myeloid Leukemia (AML), Hodgkin’s Lymphoma (HL), and Acute Respiratory Distress Syndrome (ARDS), as well as one indication in the preclinical phase, Parkinson’s disease (PD). If the fundraising is successful, PhorMed plans to enroll patients in phase II studies for ARDS and HL, while continuing its preclinical research in PD and ARDS. The company has already raised $3.5 million, with $2.75 million coming from two previous equity crowdfunding campaigns on the StartEngine platform and $750,000 from an angel investor. PhorMed is partnered with the Winship Cancer Institute at Emory University, as well as WuXi Biologics and Absorption Systems for its study drug manufacturing and pre-clinical studies. More information about the crowdfunding campaign can be found on the WeFunder page and the company’s website. Contact information for PhorMed is available through their website.
WeFunder Hosts PhorMed Inc’s Latest Regulation CF Equity Crowdfunding Campaign
In conclusion, WeFunder’s hosting of PhorMed Inc’s Regulation CF equity crowdfunding campaign provides investors with the opportunity to support a promising company in the healthcare industry. This collaboration showcases the potential for innovative financing options to help companies like PhorMed raise capital and grow their business.
In conclusion, the partnership between WeFunder and PhorMed Inc. for their Regulation CF equity crowdfunding campaign is a promising opportunity for investors to support and potentially profit from the growth of a innovative pharmaceutical company. With the support of WeFunder’s platform, PhorMed Inc. has the potential to reach a wider audience of investors and raise the necessary funds to further develop their products and services.